

1 Antimicrobial peptide novicidin synergises with rifampicin, ceftriaxone and ceftazidime against
2 antibiotic-resistant *Enterobacteriaceae* *in vitro*

3
4 Odel Soren^{a*}, Karoline Sidelmann Brinch^b, Dipesh Patel^a, Yingjun Liu^a, Alexander Liu^c, Anthony
5 Coates^a and Yanmin Hu^{a#}

6
7 Institute for Infection and Immunity, St George's, University of London, London, United Kingdom^a.
8 Novozymes A/S, Bagsvaerd, Denmark^b. John Radcliffe Hospital, University of Oxford, Oxford,
9 United Kingdom^c.

10
11 #Address correspondence to Yanmin Hu, ymhu@sgul.ac.uk

12 *Present address: Centre for Biological Sciences, University of Southampton, United Kingdom.

13
14 Running title: Novicidin Enhancement

15 Key words: *Enterobacteriaceae*, novicidin, antibiotic combination, rifampicin, ceftriaxone,
16 ceftazidime

17 ABSTRACT

18 The spread of antibiotic resistance amongst Gram-negative bacteria is a serious clinical threat and
19 infections with these organisms are a leading cause of mortality worldwide. Traditional novel drug
20 development inevitably leads to the emergence of new resistant strains, rendering the new drugs
21 ineffective. Therefore, reviving the therapeutic potentials of existing antibiotics represents an
22 attractive novel strategy. Novicidin, a novel cationic antimicrobial peptide, is effective against Gram-
23 negative bacteria. Here, we investigated novicidin as a possible antibiotic enhancer. The actions of
24 novicidin in combination with rifampicin, ceftriaxone and ceftazidime were investigated against 94

25 antibiotic resistant clinical Gram-negative isolates and 7 strains expressing New Delhi metallo- β -
26 lactamase-1 (NDM-1). Using the checkerboard method, novicidin combined with rifampicin showed
27 synergy with over 70% of the strains, reducing the minimum inhibitory concentrations (MIC)
28 significantly. The combination of novicidin with ceftriaxone and ceftazidime was synergistic against
29 89.7% of ceftriaxone-resistant strains and 94.1% of ceftazidime-resistant strains. Synergistic
30 interactions were confirmed using time kill studies with multiple strains. Furthermore, novicidin
31 increased the post-antibiotic effect (PAE) when combined with rifampicin or ceftriaxone. Membrane
32 depolarisation assays revealed that novicidin alters the cytoplasmic membrane potential of Gram-
33 negative bacteria. *In vitro* toxicology tests showed novicidin to have low haemolytic activity and no
34 detrimental effect on cell cultures. We demonstrated that novicidin strongly rejuvenates the
35 therapeutic potencies of ceftriaxone or ceftazidime against resistant Gram-negative bacteria *in vitro*.
36 In addition, novicidin boosted the activity of rifampicin. This strategy can have major clinical
37 implications in our fight against antibiotic resistant bacterial infections.

38 INTRODUCTION

39 Bacterial infections remain one of the leading causes of death worldwide. The ever escalating problem
40 of antibiotic resistance leads to the redundancy of many antibiotics, resulting in increased morbidity
41 and mortality in both developed and developing countries. In particular, the effectiveness of
42 antimicrobial agents against Gram-negative pathogens, for example *Enterobacteriaceae*, are being
43 compromised at an alarming rate (1).

44 Bacteria in the *Enterobacteriaceae* family cause an arsenal of serious infections including pneumonia,
45 wound infections, meningitis, urinary tract infections, intra-abdominal infections (1) and nosocomial
46 bacteriemia (2). Extended spectrum β -lactamase (ESBL) producing strains now predominate in many
47 areas, conferring resistance to cephalosporins and remaining sensitive only to carbapenems and the
48 older, more toxic polymyxin antibiotics such as colistin (3). Furthermore, since 2007, infections with

49 New Delhi metallo- β -lactamase 1 (NDM-1) producing ‘superbugs’ have emerged. For these infections
50 virtually all antibiotics, including carbapenems, are ineffective. Most NDM-1 strains are usually
51 susceptible only to ‘last line’ drugs like colistin, which exhibits nepro- and neuro-toxicity (4), and the
52 bacteriostatic glycylycylcline tigecycline (5). The most optimal strategy to overcome resistant infections
53 is to use novel antimicrobial agents. However, the traditional strategy of antibiotic discovery cannot
54 maintain pace with the rapid rate of resistance emergence and resistance occurs just a few years after
55 market release (6). In addition, the discovery of novel antibiotics is costly and arduous which means
56 producing large numbers of antibiotic classes within a short period of time is extremely challenging
57 (7-9).

58 Reviving the potency of existing antibiotics by combining them with novel agents is an extremely
59 desirable strategy to tackle resistance (10). Antimicrobial peptides, in particular those targeting the
60 bacterial cell envelope, have been shown to synergise with conventional antibiotics (11). The dual
61 action of weakening of the cell envelope and increasing permeability may allow the intracellular
62 antibiotic concentration to reach a lethal dose, which is unachievable by the antibiotic alone.
63 Furthermore, the use of multiple agents in combination may reduce or retard the emergence of
64 resistance to the individual antimicrobial components (10, 12).

65 It has been suggested that novicidin, a novel 18-residue cationic antimicrobial peptide, acts by
66 inserting itself into the head group region of the selectively targeted bacterial membrane bilayer. This
67 subsequently causes membrane perturbation, transient pore formation, and is bactericidal via the
68 resulting leakage of bacterial cell contents (13-15). Significant antimicrobial effects have been noted
69 with several Gram-negative organisms, such as *Escherichia coli* and *Salmonella enterica* (15).
70 Novicidin was developed from ovispirin, which in turn originated from an ovine cathelicidin known
71 as sheep myeloid antimicrobial peptide (SMAP)-29 (13). This derivation allowed for construction of
72 a peptide more suitable for use as a therapeutic agent (14).

73 In this study, we aimed to investigate the effects of novicidin in combination with conventional
74 antibiotics, namely rifampicin and third generation cephalosporins, ceftriaxone and ceftazidime,
75 against 101 Gram-negative strains including resistant *E. coli* and bacteria in the *Klebsiella*-
76 *Enterobacter-Serratia* (KES) group. Additionally, investigations were carried out to determine the
77 mechanism of action, haemolytic activity and cytotoxicity of novicidin.

78 MATERIALS AND METHODS

79 **Bacterial strains and growth conditions.** Bacterial strains used were 94 antibiotic resistant Gram-
80 negative clinical isolates including 61 *E. coli* and 33 isolates in the KES group from St Georges
81 Hospital, London. In addition, 7 strains harbouring the bla_{NDM} plasmid were used: ATCC BAA-2468,
82 BAA-2469, BAA-2470, BAA-2471, BAA-2472 and BAA-2473 and NCTC 13443. Strain ATCC
83 BAA-2468 is identified as *Enterobacter cloacae*; ATCC BAA-2469 and BAA-2471 as *E. coli*; and
84 ATCC BAA-2470, BAA-2472, BAA-2473 and NCTC 13443 as *Klebsiella pneumoniae*. Bacterial
85 strains were grown in nutrient broth no. 2 (Oxoid, UK) and on tryptone soya agar plates (Oxoid, UK).
86 Antibiotics used were as follows: rifampicin (Sanofi), ceftriaxone (Stravencon), ceftazidime
87 (Wockhardt), cefixime (Suprax) and cefotaxime (Reig Jofre). Antibiotics were prepared in water or
88 the provided solvent to an appropriate concentration. Novicidin was kindly provided by Novozymes
89 A/S, Denmark.

90 **In vitro susceptibility of novicidin and antibiotics.** The minimum inhibitory concentration (MIC) of
91 novicidin, rifampicin, ceftriaxone, ceftazidime, cefixime and cefotaxime for the 101 strains were
92 calculated using the broth micro dilution method. The MIC for each agent was identified as the lowest
93 concentration required to inhibit bacterial growth. The MIC₅₀ and MIC₉₀ were calculated, defined as
94 the lowest concentration required to inhibit growth in 50% and 90% of the strains respectively.

95 **Chequerboard assays to measure combination effects of novicidin and antibiotics.** The
96 chequerboard assay method was used for the measurement of combination effects of novicidin with

97 the antibiotics. Combinations of two drugs were prepared in 96 well plates (Fisher Scientific UK)
98 using drug concentrations starting from two fold higher than their MIC values, then serially diluted in
99 a two-fold manner. After addition of a log-phase bacterial inoculum of 1.5×10^5 colony forming units
100 (CFU)/ml, plates were incubated at 37°C for 24 hours. and then read using ELx800 absorbance
101 microplate reader (BioTek). The effects of the combinations were examined by calculating the
102 fractional inhibitory concentration index (FICI) of each combination as follows: (MIC of drug A,
103 tested in combination)/(MIC of drug A, tested alone) + (MIC of drug B, tested in combination)/(MIC
104 of drug B, tested alone). The profile of the combination was defined as synergistic if the FICI was
105 ≤ 0.5 , indifferent if the FICI was >0.5 but ≤ 4.0 and antagonistic if the FICI was >4 (16).

106 **Time kill curves of antibiotics alone and in combination with novicidin.** Two-fold serial drug
107 dilutions were prepared and added to a 96-well plate alone and in combination, and incubated at 37°C
108 with a log-phase bacterial inoculum of 1.5×10^7 CFU/ml. At 0, 1, 2, 4, 7 and 24 hours of incubation,
109 viability expressed as CFU/ml was determined by plating 100 μ l of serial dilutions onto tryptone soya
110 agar (Oxoid) plates followed by incubation at 37°C for 24 hours. Colonies were counted using
111 aCOLyte colony counter (Synbiosis) and analysed using the accompanying software. Synergistic
112 activity was defined as a ≥ 2 -log₁₀ decrease in CFU counts at 24 hours of the combination compared
113 with the most effective single agent, in addition to ≥ 2 -log₁₀ decrease compared with the 0 hour count.
114 Indifference was defined as a ≤ 1 -log₁₀ fold change in CFU counts, and antagonism as a ≥ 2 -log₁₀
115 increase in CFU at 24 hours, of the combination compared with the most effective single agent (17).

116 **Measurement of bacterial cytoplasmic membrane potential.** The permeability of the bacterial
117 cytoplasmic membrane after drug treatment was assessed using a fluorescence assay as previously
118 described (18, 19). Log-phase cultures were washed twice and resuspended in a rejuvenating buffer
119 (5 mM HEPES, pH 7.2, 20mM glucose) to an optical density of 0.05 at 600 nm. Membrane potential
120 sensitive dye DiSC3(5) (3'-Dipropylthiadicarbocyanine iodide, Sigma) was added to the resuspended
121 cells to a final concentration of 0.4 μ M and incubated until a stable reduction in fluorescence was

122 achieved as a result of DiSC3(5) uptake and cell quenching due to an intact membrane. 100 mM of
123 KCl was added to equilibrate the K⁺ ion concentration intra- and extracellularly. The bacterial cell
124 suspension was added to a 96-well microtitre plate, followed by addition of drugs in triplicate.
125 Fluorescence was measured using GloMax-Multi+ microplate reader (Promega) at an excitation
126 wavelength of 622 nm and an emission wavelength of 670 nm. Any drug induced disruption of the
127 cytoplasmic membrane resulted in an increase in measurable fluorescence.

128 **Post-Antibiotic Effect (PAE) of antibiotics alone and in combination with novicidin.** Bacteria
129 were cultured overnight at 37°C in nutrient broth. 1 ml of the culture was transferred to fresh nutrient
130 broth medium containing single or combinatory drugs. For the single drugs, 2, 5 or 10 fold higher than
131 MIC values of the drug were utilised. For the combinations, 5 fold higher than the minimal
132 enhancement concentrations of both drugs were selected according to the checkerboard results. After
133 1 hour of drug exposure, the cultures were washed three times to remove the antimicrobial agents. The
134 bacterial cells were resuspended into nutrient broth and grown at 37°C with continuous shaking at 100
135 rpm. Bacterial viability was determined by CFU counting at 0, 1, 2, 3, 4, 6 and 8 hours. The PAE
136 was calculated as follows: PAE = T – C, whereby T= time taken for drug exposed culture to increase
137 by 1 log CFU counts, and C = time taken for control culture to increase by 1 log CFU counts (20).

138 **Ex vivo haemolysis assay.** A venous blood sample from a male human donor was collected shortly
139 before testing. 10 µl aliquots of the heparinized blood were added to 0.5 ml of saline solution (0.9%
140 NaCl) containing different concentrations of novicidin in triplicate. After 1 hour of incubation at
141 37°C, the mixtures were centrifuged for 5 minutes at 5000 × g to sediment intact cells. The
142 supernatants were isolated and the absorbance values were measured at a wavelength of 545 nm.
143 Haemolysis of novicidin was analysed against negative (0% lysis) and positive controls (100% lysis)
144 to calculate the percentage of haemolysed cells, using the formulae as follows: haemolysis = $(OD_{\text{test}} -$
145 $OD_{\text{negative control}}) / (OD_{\text{positive control}} - OD_{\text{negative control}}) \times 100$. An ethic approval (H-D-2007-0055) was
146 obtained from Danish National Committee on Health Research Ethics for using human blood.

147 **Assessment of cytotoxicity using neutral-red uptake assay.** To assess the effects of cytotoxicity of
148 novicidin, the L929 mouse fibroblast cell line was utilised. Cells were grown in Eagle's minimum
149 essential medium (EMEM) with 10% foetal bovine serum (EBS) to 80% confluence. Adherent cells
150 were harvested and seeded at a concentration 5×10^5 cells per well into a 96 well microtitre plate
151 which was incubated for 24 hours at 37°C. Different concentrations of novicidin were added to the
152 cells and incubated at 37°C for 24 and 72 hours. Neutral red (25 mg/L) was added post treatment for 3
153 hours at 37°C and removed by washing the cells twice with phosphate buffered saline containing
154 $\text{CaCl}_2/\text{MgCl}_2$. Intracellular neutral red was extracted using neutral red removal solution (50% ethanol,
155 1% acetic acid and 49% water) for 15 minutes. Neutral red uptake was measured at 540 nm and cell
156 viability was determined as percentage of the untreated control. Sodium dodecyl sulphate (SDS) was
157 used as a positive control.

158 RESULTS

159 ***In vitro* susceptibility of novicidin and the antibiotics.** The MIC for novicidin, rifampicin,
160 ceftriaxone, ceftazidime, cefixime and cefotaxime were assessed for the 94 Gram-negative clinical
161 isolates and 7 NDM-1 strains. As shown in Table 1, the MIC for novicidin for the 101 strains ranged
162 from 1 to 8 mg/L with an MIC₅₀ and MIC₉₀ at 2 and 4 mg/L, respectively. The MIC for rifampicin
163 varied between 4 to >1024 mg/L. The MIC₅₀ and MIC₉₀ were 16 mg/L and 64 mg/L, respectively.
164 The MIC for ceftriaxone, ceftazidime, cefixime and cefotaxime ranged between 0.03125 and 2048
165 mg/L. The MIC₅₀ and MIC₉₀ were 1024 and 2048 mg/L for ceftriaxone, 128 and 1024 mg/L for
166 ceftazidime, 256 and 2048 mg/L for cefixime, and 512 and 2048 mg/L for cefotaxime, respectively.

167 **Chequerboard analysis of combination effects.** The combination effects of novicidin combined
168 with rifampicin, ceftriaxone and ceftazidime were determined using the broth microdilution
169 chequerboard assay against 94 clinical isolates and 7 NDM-1 strains. The FIC indices for the
170 combinations are shown in Table 2. The combination of novicidin with rifampicin was shown to have

171 synergistic activity with over 70% of both *E. coli* and isolates in KES group, with FIC indices
172 between 0.018 and 0.5. In addition, the combination was shown to have synergistic effects with all 7
173 NDM-1 strains. Novicidin reduced the MIC of rifampicin between 2 to 512-fold, with the majority of
174 strains exhibiting 4 or 8-fold reductions in MIC values (Supplementary Table 1, 2 and 3). Novicidin
175 combined with ceftriaxone showed synergy with 57.4% of the *E. coli* strains and 69.7% of isolates in
176 KES group. The combination of novicidin with ceftazidime presented synergy with 63.9% of the *E.*
177 *coli* strains and 78.8% of isolates in KES group. The FIC indices for the NDM-1 strains were unable
178 to be determined as the MIC for ceftriaxone and ceftazidime was higher than the maximum achievable
179 chequerboard concentration of 2048 mg/L. As revealed in Table 3, synergistic activities were shown
180 in the majority (89.7%) of the ceftriaxone-resistant strains compared to a minority of the ceftriaxone-
181 sensitive strains (16.7%). A similar pattern was observed with the novicidin and ceftazidime
182 combination, whereby synergy was seen in 94.1% of resistant strains compared with 3.8% of sensitive
183 strains. Novicidin reduced the MIC of ceftriaxone or ceftazidime between 2 to more than 2048-fold
184 (Supplementary Table 1 and 2).

185 **Time kill assays confirming synergy of novicidin combined with rifampicin, ceftriaxone or**
186 **ceftazidime.** Time kill assays were performed to examine the activities of novicidin in combination
187 with rifampicin, ceftriaxone and ceftazidime against 5 strains of *E. coli* and KES group clinical strains
188 which represented an FIC index <0.5 for each drug combination. The combination of rifampicin and
189 novicidin was also tested against the 7 NDM-1 strains. A range of different concentrations was tested
190 according to chequerboard analysis and the most effective and synergistic activities are shown. As
191 seen in Figure 1, rifampicin at 2 mg/L (Fig. 1A and Fig. 1B) and at 256 mg/L (Fig. 1C and 1D) failed
192 to reduce the viability of the clinical isolate and the NDM-1 *E. coli*, novicidin at 0.5 or 0.25 mg/L
193 (Fig. 1A and 1B) and at 4 or 2 mg/L (Fig. 1C and 1D) showed initial kill of the bacteria but regrowth
194 was seen. However, when rifampicin at 2 mg/L combined with novicidin at 0.5 (Fig. 1A) or 0.25 (Fig.
195 1B) mg/L, 100% kill of the *E. coli* cells was achieved at 2 and 4 hours post treatment, respectively.

196 Similarly, when rifampicin at 256 mg/L combined with novicidin at 4 (Fig. 1C) or 2 (Fig. 1D) mg/L,
197 complete kill of the NDM-1 *E. coli* was seen at 4, 7 and 24 hours post treatment, respectively. There
198 were significant differences in the reduction of CFU counts between the combination of novicidin
199 with rifampicin and each of the single drug (rifampicin or novicidin) treatment ($P < 0.0001$).

200 Novicidin and ceftriaxone combinations were tested against ceftriaxone resistant *E. coli* and KES
201 group clinical isolates. As seen in Fig. 1E, 1F, 1G and 1H, ceftriaxone at 2048 mg/L was unable to
202 reduce the CFU counts of both strains. However, when novicidin was added in the culture at 1 or 0.5
203 mg/L and 2 or 1 mg/L, the bacterial cells were rapidly killed showing 100% reduction in CFU count at
204 2 or 4 hours post treatment for the *E. coli* isolate respectively (Fig. 1E and 1F), and at 1 or 2 hours
205 post treatment for the KES group strain (Fig. 1G and 1H) respectively, demonstrating significant
206 synergy. There were significant differences in the reduction of CFU counts between combination of
207 novicidin with ceftriaxone and each of the single drug (ceftriaxone or novicidin) treatment
208 ($P < 0.0001$). The ability of novicidin enhancement to rifampicin or ceftriaxone was also compared
209 with another defensin, plectasin which was neither bactericidal on its own nor boosting the activity of
210 rifampicin (Fig. 1I) or ceftriaxone (Fig. 1J) against Gram-negative bacteria to validate the assay.
211 Similar patterns of combination activities were observed for the strains tested when novicidin was
212 combined with ceftazidime (data not shown).

213 **Membrane permeabilising effects of novicidin against *E. coli* and KES group isolates.** The effects
214 of novicidin at the cytoplasmic bacterial membrane with both *E. coli* and an isolate from the KES
215 group were investigated with fluorescence assays. Immediately after novicidin exposure, a sharp
216 concentration dependent increase in fluorescence occurs with the *E. coli* strain (Fig. 2) indicating
217 disruption of the bacterial membrane which led to the leakage of the fluorescent dye. A similar effect
218 was observed when novicidin was used to treat the strain in the KES group despite only high
219 concentrations of novicidin such as 64 and 32 mg/L resulting in an increase in fluorescence (data not
220 shown).

221 **Post-antibiotic effect of novicidin and novicidin-antibiotic combinations.** The PAE of novicidin,
222 rifampicin or ceftriaxone singly and in combination was determined; rifampicin was used at 5-fold
223 higher than the MIC level and ceftriaxone at 10-fold higher than the MIC level. As novicidin was
224 rapidly bactericidal at 5-fold higher than its MIC concentration, 2-fold higher than MIC level was
225 used to induce the PAE. Due to their enhanced synergistic activities, the same concentrations for
226 novicidin and rifampicin or ceftriaxone used singly for PAE induction would completely kill all the
227 bacterial cells within 1 hour if combined. Therefore, to induce PAE with combination treatment, 5-
228 fold higher than the minimal enhancement concentrations for novicidin and rifampicin or ceftriazone
229 were used, chosen from checkerboard results. As shown in Fig. 3A, the PAE of both novicidin and
230 rifampicin was estimated as 52.8 minutes for the *E. coli* strain. The novicidin and rifampicin
231 combination doubled the PAE to 121.8 minutes despite substantially lower concentrations being used
232 ($P<0.0001$). As shown in Fig. 3B, the PAE of novicidin was 84 minutes and ceftriaxone produced no
233 PAE. The novicidin and ceftriaxone combination exhibited a prolonged PAE of 117 minutes
234 ($P<0.0001$).

235 **Haemolytic effects of novicidin.** Haemolysis of novicidin was tested using human blood. As shown
236 in Table 4, at the lowest tested novicidin concentration of 125 mg/L, haemolysis occurred at a rate of
237 4.4% ranging up to 19.9% at the highest tested concentration of 1000 mg/L. The 50% haemolytic
238 concentration could not be accurately predicated due to the non-linear correlation between novicidin
239 concentration and haemolysis, however is shown to be >1000 mg/L from the current data.
240 Extrapolation provides an estimate of between 2500 and 3000 mg/L. 100% haemolysis was seen
241 when the blood was added into distilled water (Table 4). The experiments were repeated twice with
242 reproducible results.

243 **Determination of cytotoxicity by neutral-red uptake.** To assess the cytotoxicity of novicidin,
244 neutral-red uptake was measured after treatment of the murine fibroblasts with different
245 concentrations of novicidin. As seen in Table 5, cell viability was well conserved and remained

246 between 93% to 99% after 24 hours of novicidin exposure, and 98% to 102% after 72 hours exposure
247 for all tested concentrations. This indicates low levels of general cytotoxicity even with prolonged
248 exposure. SDS was used as a positive control: concentrations of 80, 100 and 120 mg/L reduced cell
249 viability to 80%, 9% and 0% at 24 hours and 55%, 0% and 0% at 72 hours, respectively, confirming
250 the validity of the assay. The experiments were repeated twice with reproducible results.

251 DISCUSSION

252 Novicidin is a newly derived antimicrobial peptide. In this study, we demonstrated for the first time
253 that novicidin synergised with rifampicin and third generation cephalosporins (ceftriaxone and
254 ceftazidime) against Gram-negative antibiotic-resistant bacterial strains *in vitro*. The 94 clinical
255 isolates from the *Enterobacteriaceae* family covered a broad host distribution in the South London
256 area and the 7 NDM-1 strains represented the most resistant type of Gram-negative bacteria. Most of
257 the ceftriaxone and ceftazidime resistant bacteria were also resistant to cefotaxime and cefixime
258 indicating these were ESBL producing strains.

259 Rifampicin is an important component of the combination regimen used for the treatment of
260 tuberculosis and many Gram-positive bacterial infections (21). Rifampicin is not considered to be
261 standard treatment for *Enterobacteriaceae* infections, and thus a breakpoint for resistance is not
262 available. Our results showed that the MIC₅₀ and MIC₉₀ for rifampicin were 16 and 32 mg/L,
263 respectively. Recently, rifampicin has been introduced in combination therapy for the treatment of
264 infections caused by multi-drug resistant Gram-negative bacteria (22, 23). Our checkerboard analysis
265 reveals that the combination of novicidin and rifampicin showed synergistic effects with over 70% of
266 the tested strains with marginally higher effectiveness with the bacterial strains in KES group
267 compared with *E. coli*. Novicidin was able to revive the activity of rifampicin by reduction of
268 rifampicin MIC between 2 to 512 fold. The combination was also synergistic with all of the strains
269 harbouring NDM-1 plasmids. Synergistic activity of novicidin with rifampicin was confirmed using

270 time kill assays, a method allowing for a more dynamic analysis of bactericidal and combinatorial
271 effects. Time kill assays were performed with multiple strains, repeatedly demonstrating that at
272 concentrations at which both novicidin and rifampicin were ineffective alone, when combined, rapid
273 bactericidal activities were seen with 100% elimination of the bacterial cells within a few hours of
274 drug exposure, which substantially speeded up the treatment duration. Rifampicin alone required
275 higher concentrations such as 128 mg/L to completely eradicate *E. coli* cells in culture (data not
276 shown) and this concentration was only able to reduce the CFU counts of a KES group strain by 2
277 logs (data not shown). However when combined with novicidin at 0.5 or 1 mg/L, rifampicin at
278 concentrations of just 2 mg/L killed 100% of the bacterial cells at 4 or 2 hours post treatment (Fig. 1A
279 and 1B). The combination was also able to enhance the activities of rifampicin against the NDM-1
280 strains (Fig. 1C and 1D), however required high rifampicin concentrations.

281 Novicidin also enhanced the activities of ceftriaxone and ceftazidime. Interestingly, the majority of
282 synergy was observed with those strains showing resistance to ceftriaxone or ceftazidime. This was
283 also confirmed with time kill assays tested against multiple strains. Ceftriaxone has a long half-life
284 and is used to treat septicaemia, pneumonia, meningitis and urinary tract infections. Clinical
285 pharmacokinetic data revealed that after a single intravenous injection of a standard 2000 mg dose, the
286 plasma C_{max} was approximately 257 mg/L and at 24 hours post administration, the plasma
287 concentration was approximately 15 mg/L. However, in the urine, the C_{max} of ceftriaxone was
288 approximately 2692 mg/L within 2 hours following 2000 mg intravenously administered (24).
289 Ceftazidime, like ceftriaxone, has broad spectrum activity and is one of the few agents in this class to
290 be used clinically against *Pseudomonas* spp. Ceftazidime pharmacokinetic data shows comparative
291 serum C_{max}, as a 1000 mg intravenous dose produced a peak concentration of approximately 140
292 mg/L. Similarly, much higher concentrations are present in the urine. Up to 6 hours post infusion of a
293 50 mg/kg dose of ceftazidime, the concentration in collected urine samples ranged from 2370 to 11,
294 340 mg/L, with approximately 75% of the drug being recovered unchanged (25). Based on this data, it

295 may be argued that novicidin-cephalosporin combinations may not be clinically appropriate for the
296 treatment of septicaemia as 2048 mg/L appears to be an unattainable serum concentration. However,
297 pharmacokinetic analysis of novicidin in combination with the antibiotics may give more realistic
298 estimations of the concentrations required to achieve synergistic and bactericidal effect. Nevertheless,
299 the extremely high concentrations of both ceftriaxone and ceftazidime in the urine indicate that either
300 of these in combination with novicidin may be clinically applicable in treating urinary tract infections.

301 The combination of novicidin with rifampicin or ceftriaxone was able to suppress bacterial growth
302 against our tested bacterial strains after the drugs had been removed. Interestingly, although
303 ceftriaxone alone was unable to produce a PAE (26), a prolonged PAE was generated in the
304 combination with novicidin. Therefore, novicidin and the antibiotic combinations, possibly by
305 prolonging the PAE, are able to reduce the likelihood of resistance development. A longer PAE also
306 contributes a therapeutic advantage in devising dosing intervals for drug regimens. Generally a longer
307 PAE enables less frequent drug doses whilst maintaining therapeutic efficacy; this can reduce adverse
308 effects and increase patient compliance (20).

309 The precise mechanism underlying the antibiotic enhancing activities of novicidin is unclear. Due to
310 decreased cell envelope permeability and altered efflux-pump systems, Gram-negative bacteria are
311 intrinsically resistant to many antibiotics, such as rifampicin. Rifampicin inhibits bacterial DNA-
312 dependant RNA polymerase (23) and its action on bacterial cells is concentration dependent. It has
313 been shown that compounds which target the cell wall or cell membrane were found to potentiate the
314 activities of other antibiotics (11, 18, 27, 28). Previous work on artificial membranes showed that low
315 concentrations of novicidin resulted in transient pore formation and increased concentrations cause
316 cell membrane disruption (13, 29). It is also suggested that novicidin accumulates on the membrane
317 surface until a detergent-like disintegration occurred (known as the carpet mechanism) (13).
318 Consistent with this finding, we showed that novicidin disturbed the cytoplasmic membrane potential
319 by depolarising the membrane, and even at very low concentrations, significant fluorescence release

320 was observed. It is likely that the enhanced activities of rifampicin by novicidin was due to increased
321 cell membrane permeability against the Gram-negative bacteria leading to higher intracellular
322 accumulation of rifampicin (30, 31).

323 Cephalosporins are β -lactam antibiotics and interact with transpeptidases also known as penicillin
324 binding proteins (PBP) (32), blocking the terminal step in bacterial cell wall biosynthesis (33).
325 Accordingly, the synergy between novicidin and ceftriaxone or ceftazidime may be attributed to a
326 'double hit' mechanism: (1) the disruption of the membrane by novicidin, and (2) the inhibition of cell
327 wall biosynthesis by ceftriaxone or ceftazidime, which may be sufficient in reducing the integrity of
328 the cell envelope, resulting in cell death. Our checkerboard analysis showed that synergy was more
329 likely with ceftriaxone or ceftazidime resistant strains, and resistance to such agents is usually due to
330 the acquisition of plasmids carrying ESBL genes, producing enzymes which hydrolyse the β -lactam
331 ring of antibiotics. It is unclear how novicidin enhances the activities of these cephalosporins against
332 resistant strains. We hypothesized that the enhanced antibiotic activities was likely due to the action of
333 pore formation by novicidin, leading to the elimination of enzymes or plasmids, the resistance
334 determinants. However, this notion needs to be further tested.

335 The findings from our study demonstrate proof of concept, displaying the potential of peptide-
336 antibiotic combinations which undoubtedly contribute to important clinical applications. Firstly, our
337 demonstration of novicidin as a powerful antibiotic enhancer strongly illustrates that other similar
338 peptides or compounds may potentially be beneficial above and beyond their direct anti-microbial
339 properties. Secondly, addition of novicidin reduced MICs and improved the rate of bactericidal
340 activities of antibiotics, therefore highly resistant Gram-negative bacteria which are extremely
341 difficult to kill can be eliminated from the bacterial culture. Finally, novicidin exhibited a very low
342 haemolytic activity which was in agreement with those found by Dorosz et al (14). In addition,
343 novicidin was non-toxic and cell viability was well conserved after treatment with different
344 concentrations of novicidin. Combination therapy with novicidin shows promise for becoming a novel

345 and much clinically desired therapeutic option to treat “superbug” infections. *In vivo* work is under
346 way aiming to expose the therapeutic potential of novicidin in the combination regimen to treat
347 infections caused by antibiotic resistant Gram-negative bacteria.

348 ACKNOWLEDGMENTS

349 This work was funded with support from the European Commission under grant agreement no:
350 278998, BacAttack. This communication reflects the views only of the author, and the Commission
351 cannot be held responsible for any use which may be made of the information contained therein.

352 We would like to thank Dr Julie Johnson from St George’s Healthcare NHS Trust for kindly
353 providing the clinical strains and Novozymes A/S Denmark for providing novicidin.

354 REFERENCES

- 355 1. **Paterson DL.** 2006. Resistance in gram-negative bacteria: *Enterobacteriaceae*. *Am J Infect Control*
356 **34**:S20-28; discussion S64-73.
- 357 2. **Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW.** 2005. Bloodstream infections
358 caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of
359 inappropriate initial antimicrobial therapy on outcome. *Antimicrob Agents Chemother* **49**:760-766.
- 360 3. **Pitout JD, Laupland KB.** 2008. Extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: an
361 emerging public-health concern. *Lancet Infect Dis* **8**:159-166.
- 362 4. **Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM.** 2012. Colistin: an update on the
363 antibiotic of the 21st century. *Expert Rev Anti Infect* **10**:917-934.
- 364 5. **Nordmann P, Poirel L, Toleman MA, Walsh TR.** 2011. Does broad-spectrum beta-lactam resistance
365 due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-
366 negative bacteria? *J Antimicrob Chemoth* **66**:689-692.
- 367 6. **Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ.** 2010. Challenges of antibacterial discovery
368 revisited. *Ann NY Acad Sci* **1213**:5-19.
- 369 7. **Coates AR, Halls G, Hu Y.** 2011. Novel classes of antibiotics or more of the same? *Brit J Pharmacol*
370 **163**:184-194.
- 371 8. **Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H.** 2004. Antibacterial research and
372 development in the 21(st) Century--an industry perspective of the challenges. *Curr Opin Microbiol*
373 **7**:445-450.
- 374 9. **Livermore DM, British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need:
375 Regenerating Antibacterial Drug D, Development.** 2011. Discovery research: the scientific challenge
376 of finding new antibiotics. *J Antimicrob Chemoth* **66**:1941-1944.
- 377 10. **Kalan L, Wright GD.** 2011. Antibiotic adjuvants: multicomponent anti-infective strategies. *Expert Rev*
378 *Mol Med* **13**:e5.
- 379 11. **Hu Y, Liu A, Vaudrey J, Vaiciunaite B, Moigboi C, McTavish SM, Kearns A, Coates A.** 2015.
380 Combinations of beta-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against
381 Methicillin-Sensitive and Methicillin-Resistant *Staphylococcus aureus*. *PLoS ONE* **10**:e0117664.

- 382 12. **Soothill G, Hu Y, Coates A.** 2013. Can we prevent antimicrobial resistance by using antimicrobials
383 better? *Pathogens* **2**:422-435.
- 384 13. **Nielsen SB, Otzen DE.** 2010. Impact of the antimicrobial peptide Novicidin on membrane structure
385 and integrity. *J Colloid Interf Sci* **345**:248-256.
- 386 14. **Dorosz J, Gofman Y, Kolusheva S, Otzen D, Ben-Tal N, Nielsen NC, Jelinek R.** 2010. Membrane
387 interactions of novicidin, a novel antimicrobial peptide: phosphatidylglycerol promotes bilayer
388 insertion. *J Phys Chem B* **114**:11053-11060.
- 389 15. **Balakrishnan VS, Vad BS, Otzen DE.** 2013. Novicidin's membrane permeabilizing activity is driven by
390 membrane partitioning but not by helicity: a biophysical study of the impact of lipid charge and
391 cholesterol. *Biochim Biophys Acta* **1834**:996-1002.
- 392 16. **Odds FC.** 2003. Synergy, antagonism, and what the chequerboard puts between them. *J Antimicrob*
393 *Chemoth* **52**:1.
- 394 17. **White RL, Burgess DS, Manduru M, Bosso JA.** 1996. Comparison of three different in vitro methods of
395 detecting synergy: time-kill, checkerboard, and E test. *Antimicrob Agents Chemother* **40**:1914-1918.
- 396 18. **Hu Y, Coates AR.** 2012. Enhancement by novel anti-methicillin-resistant *Staphylococcus aureus*
397 compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in
398 vivo studies. *J Antimicrob Chemoth.* **68**:374-84.
- 399 19. **Wu M, Hancock RE.** 1999. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the
400 outer and cytoplasmic membrane. *J Biol Chem* **274**:29-35.
- 401 20. **Spivey JM.** 1992. The postantibiotic effect. *Clin Pharm* **11**:865-875.
- 402 21. **Rodriguez-Pardo D, Pigrau C, Corona PS, Almirante B.** 2015. An update on surgical and antimicrobial
403 therapy for acute periprosthetic joint infection: new challenges for the present and the future. *Expert*
404 *Rev Anti-Infe* **13**:249-265.
- 405 22. **Nastro M, Rodriguez CH, Monge R, Zintgraff J, Neira L, Rebollo M, Vay C, Famiglietti A.** 2014. Activity
406 of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-
407 negative bacteria. *J Chemother* **26**:211-216.
- 408 23. **Drapeau CM, Grilli E, Petrosillo N.** 2010. Rifampicin combined regimens for gram-negative infections:
409 data from the literature. *Int J Antimicrob Ag* **35**:39-44.
- 410 24. **Patel IH, Chen S, Parsonnet M, Hackman MR, Brooks MA, Konikoff J, Kaplan SA.** 1981.
411 Pharmacokinetics of ceftriaxone in humans. *Antimicrob Agents Chemother* **20**:634-641.
- 412 25. **Leeder JS, Spino M, Tesoro AM, MacLeod SM.** 1983. High-pressure liquid chromatographic analysis of
413 ceftazidime in serum and urine. *J Antimicrob Chemoth* **24**:720-724.
- 414 26. **Burgess DS.** 2005. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial
415 treatment of *Pseudomonas aeruginosa* infections. *Clin Infect Dis* **40 Suppl 2**:S99-104.
- 416 27. **Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Fortuna M, Drenaggi D, Scalise G.** 2000. In vitro
417 activities of membrane-active peptides alone and in combination with clinically used antimicrobial
418 agents against *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **44**:1716-1719.
- 419 28. **Anantharaman A, Rizvi MS, Sahal D.** 2010. Synergy with rifampin and kanamycin enhances potency,
420 kill kinetics, and selectivity of de novo-designed antimicrobial peptides. *Antimicrob Agents Chemother*
421 **54**:1693-1699.
- 422 29. **Bertelsen K, Dorosz J, Hansen SK, Nielsen NC, Vosegaard T.** 2012. Mechanisms of peptide-induced
423 pore formation in lipid bilayers investigated by oriented 31P solid-state NMR spectroscopy. *PLoS ONE*
424 **7**:e47745.
- 425 30. **Pages JM, Sandrine AF, Mahamoud A, Bolla JM, Davin-Regli A, Chevalier J, Garnotel E.** 2010. Efflux
426 pumps of gram-negative bacteria, a new target for new molecules. *Curr Top Med Chem* **10**:1848-
427 1857.
- 428 31. **Zechini B, Versace I.** 2009. Inhibitors of multidrug resistant efflux systems in bacteria. *Recent Pat Anti*
429 *infect Drug Discov* **4**:37-50.
- 430 32. **Barbas JA, Diaz J, Rodriguez-Tebar A, Vazquez D.** 1986. Specific location of penicillin-binding proteins
431 within the cell envelope of *Escherichia coli*. *J Bacteriol* **165**:269-275.

- 432 33. **Kosowska-Shick K, McGhee PL, Appelbaum PC.** 2010. Affinity of ceftaroline and other beta-lactams
433 for penicillin-binding proteins from *Staphylococcus aureus* and *Streptococcus pneumoniae*. *Antimicrob*
434 *Agents Chemother* **54**:1670-1677.
- 435
- 436
- 437

Table 1. MIC values for novicidin and antibiotics used in this study.











	MIC range (mg/L)	MIC50 (mg/L)	MIC90 (mg/L)
Novicidin	1 - 8	2	4
Rifampicin	4 - >1024	16	32
Ceftriaxone	0.03125 - >2048	1024	2048
Cefixime	0.03125 - >2048	256	2048
Ceftazidime	0.03125 - >2048	128	1024
Cefotaxime	0.03125 - >2048	512	2048

Table 2. Combination activity of novicidin with rifampicin, ceftriaxone and ceftazidime against the 101 Gram-negative *Enterobacteriaceae* strains


Strains	Combination Activity	FICI	Total no. (%) of strains with activity when novicidin combined with		
			Rifampicin	Ceftriaxone	Ceftazidime
<i>E. coli</i>	Synergy	≤0.5	43 (70.5%)	35 (57.4%)	39 (63.9%)
	Indifferent	>0.5 <4	18 (29.5%)	26 (42.6%)	22 (36.1%)
	Antagonism	≥4	0	0	0
Isolates in KES group	Synergy	≤0.5	28 (84.8%)	23 (69.7%)	26 (78.8%)
	Indifferent	>0.5 <4	5 (15.2%)	10 (30.3%)	7 (21.2%)
	Antagonism	≥4	0	0	0
NDM-1 strains	Synergy	≤0.5	7 (100%)	-	-
	Indifferent	>0.5 <4	0	-	-
	Antagonism	≥4	0	-	-

Table 3. Combination activity of novicidin with ceftriaxone and ceftazidime against the 94 Gram-negative clinical isolates

Strains (total no.)	Total no. (%) of strains with activity of novicidin combined with ceftriaxone and ceftazidime		
	Synergy	Indifferent	Antagonism
	FICI \leq 0.5	FICI $>$ 0.5 $<$ 4	FICI \geq 4
Ceftriaxone resistant strains [58]	52 (89.7%)	6 (10.3%)	0
Ceftriaxone sensitive strains [36]	6 (16.7%)	30 (83.3%)	0
Ceftazidime resistant strains [68]	64 (94.1%)	4 (5.9%)	0
Ceftazidime sensitive strains [26]	1 (3.8%)	25 (96.2%)	0





1 FIG 1 Time-kill analysis showing the effects of novicidin in combination with rifampicin,
2 ceftriaxone and ceftazidime against antibiotic resistant *E. coli* and strains. The peptide and
3 antibiotics alone or each combined with novicidin were added to the bacterial cultures and
4 CFU counts were carried out at different time points. Combination of rifampicin at 2 mg/L
5 and novicidin at 1 mg/L (A) or 0.5 mg/L (B) against a clinical isolate of *E. coli*. Combination
6 of rifampicin at 256 mg/L and novicidin at 4 mg/L (C) or 2 mg/L (D) against a NDM-1 *E.*
7 *coli*. Combination of ceftriaxone at 2048 mg/L and novicidin at 1 mg/L (E) or 0.5 mg/L (F)
8 against a clinical isolate of *E. coli*. Combination of ceftriaxone at 2048 mg/L and novicidin at
9 2 mg/L (G) or 1 mg/L (H) against a clinical isolate of the KES group. Negative controls
10 were included as (I) combination of plectasin at 32 mg/L with rifampicin at 256 mg/L against
11 a DN1-1 *E. coli* and (J) combination of plectasin at 32 mg/L with ceftriaxone at 2048 mg/L
12 against a clinical isolate of the KES group. These results shown are mean with standard
13 deviation (SD) of two independent experiments.



1 FIG 2 Determination of cytoplasmic membrane potential by novicidin against a clinical
2 isolate of *E. coli*. Log phase *E. coli* culture was incubated with DiSC3(5) to a final
3 concentration of 0.4 μ M until no more quenching was detected, which was followed by
4 addition of 0.1 M KCl. Novicidin were incubated with the cultures at different
5 concentrations. The changes in fluorescence were monitored at various time points. The data
6 was mean with SD of two independent experiments.

7



1 FIG 3 Induction of PAE of rifampicin (A) and ceftriaxone (B) by novicidin against a clinical
2 isolate of *E. coli*. Concentrations used for single drug PAE induction are rifampicin 80 mg/L,
3 novicidin 2 mg/L and ceftriaxone 1024 mg/L. For combination PAE induction, rifampicin
4 was 20 mg/L and novicidin was 0.625 mg/L; ceftriaxone was 640 mg/L and novicidin was
5 0.625 mg/L. The data was mean with SD of two independent experiments.
6

Table 4. The haemolytic effects of novicidin at different concentrations

Novicidin concentration (mg/L)	Haemolysis (%)
125	4.4
250	7.7
500	13.2
750	13.3
1000	19.9
Negative control*	0
Positive control**	100

*blood was mixed with saline solution. **blood was mixed with distilled water

Table 5. Cell viability following treatment with novicidin assessed via neutral red uptake

	Concentrations (mg/L)	Viability (%)	
		24 hours	72 hours
Novicidin	0	100	100
	25	95	102
	50	93	102
	100	99	98
	200	99	101
SDS	80	80	55
	100	9	0
	120	0	0